Trial · NCT02695420
Results by group47
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 47
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg BID | Week 2 | 239 | Standard Deviation 106 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Week 2 | 179 | Standard Deviation 77.1 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Week 2 | 208 | Standard Deviation 61.6 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg BID | Week 4 | 222 | Standard Deviation 63.5 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Week 4 | 196 | Standard Deviation 44 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Week 4 | 209 | Standard Deviation 61.9 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg BID | Week 12 | 217 | Standard Deviation 66.1 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Week 12 | 228 | Standard Deviation 56.9 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Week 12 | 282 | Standard Deviation 120 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg BID | Week 16 | 206 | Standard Deviation 84.5 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | Week 16 | 244 | Standard Deviation 67.7 | ng/mL |
| Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | Week 16 | 292 | Standard Deviation 118 | ng/mL |
| PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8) | Omecamtiv Mecarbil 25 mg BID | 1850 | Standard Deviation 563 | hr*ng/mL | |
| PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8) | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | 1850 | Standard Deviation 383 | hr*ng/mL | |
| PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8) | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | 2360 | Standard Deviation 465 | hr*ng/mL | |
| Change From Baseline at Week 16 in Systolic Ejection Time (SET) | Placebo BID | -1.7 | Standard Error 4.7 | msec | |
| Change From Baseline at Week 16 in Systolic Ejection Time (SET) | Omecamtiv Mecarbil 25 mg BID | 20.5 | Standard Error 4.9 | msec | |
| Change From Baseline at Week 16 in Systolic Ejection Time (SET) | Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose | 27.6 | Standard Error 5.4 | msec | |
| Change From Baseline at Week 16 in Systolic Ejection Time (SET) | Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose | 23.8 | Standard Error 5.2 | msec | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo BID | All TEAEs | 14 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02695420/results